season
influenza
epidem
influenza
pandem
caus
influenza
viru
iav
result
million
death
world
develop
antiiav
vaccin
therapeut
urgent
need
prevent
treatment
iav
infect
control
futur
influenza
pandem
hemagglutinin
ha
iav
play
critic
role
viral
bind
fusion
entri
contain
major
neutral
epitop
therefor
ha
attract
target
develop
antiiav
drug
vaccin
review
recent
progress
studi
conform
chang
ha
viral
fusion
process
develop
habas
antivir
therapeut
vaccin
influenza
continu
pose
seriou
threat
public
health
worldwid
sinc
season
influenza
epidem
affect
popul
result
death
worldwid
year
http
wwwwhointcsrdiseas
influenzaresearchagendadocumentpdf
influenza
pandem
like
flu
pandem
spanish
flu
may
lead
million
death
taubenberg
new
influenza
pandem
caus
novel
swineorigin
influenza
viru
soiv
result
million
infect
countri
oversea
territori
commun
http
wwwwhointcsrdon
miller
et
al
smith
et
al
itoh
et
al
rapid
spread
soiv
human
worldwid
continu
mutat
soiv
protein
pan
jiang
pan
et
al
suggest
newli
emerg
animalorigin
viru
acquir
potent
humantohuman
transmiss
rais
grow
concern
evolut
highli
pathogen
avian
influenza
hpai
virus
caus
fatal
case
among
total
infect
individu
march
casefat
rate
http
wwwwhointcsrdiseas
real
mortal
rate
closer
base
surveil
seropreval
studi
conduct
sever
countri
li
et
al
influenza
viru
consist
three
genera
b
c
although
three
type
influenza
virus
abl
infect
human
influenza
viru
iav
may
caus
influenza
pandem
watt
base
antigen
two
surfac
proteinshemagglutinin
ha
neuraminidas
na
iav
classifi
differ
subtyp
includ
ha
na
subtyp
yamashita
et
al
ha
respons
viral
entri
russel
et
al
contain
major
neutral
epitop
ndifon
et
al
thu
serv
attract
target
drug
vaccin
develop
transfer
cell
surfac
golgi
apparatu
proteolyt
cleav
function
subunit
link
singl
disulfid
bond
influenza
viru
strain
contain
ha
cleavag
site
singl
basic
amino
acid
residu
cleav
tissu
restrict
proteas
therebi
limit
spread
infect
host
cleavag
occur
cell
surfac
releas
virus
subtyp
virus
caus
epidem
cleavag
may
mediat
serin
proteas
tryptas
clara
produc
clara
cell
bronchiolar
epithelium
kido
et
al
enzym
show
recognit
specif
sequenc
qexr
found
cleavag
site
contrast
hpai
subtyp
polypeptid
chain
separ
polybas
sequenc
insert
cleavag
site
perdu
et
al
case
cleavag
intracellular
involv
subtilisinlik
enzym
activ
posttransl
process
hormon
growth
factor
precursor
et
al
furin
recognit
sequenc
rxrkr
common
featur
insert
polybas
sequenc
wide
tissu
distribut
furinlik
enzym
high
effici
intracellular
cleavag
compar
extracellular
cleavag
appear
relat
widespread
system
virul
infect
caus
virus
bird
local
outbreak
infect
human
hong
kong
steinhauer
receptor
iav
sialic
acid
wei
et
al
bullough
et
al
liu
et
al
depend
speci
infect
receptor
recognit
vari
specif
natur
glycosid
linkag
sialic
acid
penultim
sugar
sidechain
roger
paulson
exampl
human
iav
bind
sialic
acid
predomin
upper
human
respiratori
tract
matrosovich
et
al
wherea
avian
iav
prefer
sialic
acid
galactos
predomin
avian
enter
tract
naev
et
al
fig
therefor
ha
key
compon
anim
iav
becom
transmiss
human
instanc
iav
may
acquir
humantohuman
transmiss
ha
gain
abil
bind
receptor
steven
et
al
xu
et
al
bind
receptor
viru
taken
cell
endocytosi
within
endosom
compart
virion
expos
increas
acid
ph
ha
protein
undergo
irrevers
conform
chang
metast
prefus
conform
lowph
hairpin
structur
involv
extrus
fusion
peptid
fp
interior
neutralph
structur
toward
endosom
membran
promot
fusion
viral
endosom
membran
harrison
reed
et
al
xray
crystallograph
studi
demonstr
extens
rearrang
residu
low
ph
respect
rel
orient
coilcoil
format
looptohelix
helixtoloop
transit
bullough
et
al
durrer
et
al
plotch
et
al
harrison
initi
step
detrimer
membran
distal
domain
trigger
low
ph
domain
remain
tether
innercor
triplestrand
coil
coil
structur
region
residu
bizebard
et
al
step
driven
electrostat
forc
posit
charg
favor
electrostat
interact
neg
charg
neutral
ph
short
helix
residu
extend
loop
residu
ntermin
region
becom
extens
central
triplestrand
coil
coil
nativ
ha
form
long
helix
residu
reloc
fp
origin
buri
posit
time
middl
portion
residu
long
helix
convert
loop
allow
second
half
long
helix
jackknif
back
lie
antiparallel
first
half
fig
result
format
hairpin
structur
common
conform
present
class
transmembran
protein
envelop
virus
kielian
rey
harrison
interact
fp
target
membran
lead
extend
intermedi
bridg
viral
cell
membran
intermedi
collaps
zip
ctermin
part
ectodomain
alongsid
trimerclust
ntermin
part
bring
two
membran
close
proxim
result
format
hemifus
stalk
fusion
pore
open
genet
materi
iav
releas
host
cell
gener
new
virion
harrison
cleavag
ha
precursor
subunit
host
cell
proteas
especi
airway
tryptas
clara
kido
et
al
miniplasmin
murakami
et
al
ectop
pancreat
trypsin
le
et
al
essenti
subsequ
step
viral
replic
liu
et
al
okumura
et
al
therefor
molecul
block
cleavag
may
inhibit
iav
infect
kido
et
al
sever
serin
proteas
inhibitor
aprotinin
peptid
zhirnov
et
al
leupeptin
also
known
nacetyllleucyllleucyllarginin
tashiro
et
al
et
al
eaminocapro
acid
kido
et
al
nafamostat
hosoya
et
al
fig
pulmonari
surfact
surfaceact
lipoprotein
complex
phospholipoprotein
produc
type
ii
alveolar
cell
kido
et
al
human
mucu
proteas
inhibitor
beppu
et
al
shown
reduc
ha
cleavag
iav
infect
cultur
anim
model
aprotinin
trasylol
bayer
bovin
pancreat
trypsin
inhibitor
use
inject
drug
reduct
bleed
complex
surgeri
howev
trasylol
withdrawn
market
may
studi
suggest
use
increas
risk
complic
death
http
sever
fda
approv
pulmonari
surfact
market
includ
exosurf
curosurf
infasurf
survanta
increas
pulmonari
complianc
prevent
infant
respiratori
distress
syndrom
ird
long
protein
cell
figur
diagram
phinduc
conform
chang
subunit
prefus
postfus
state
prefus
state
neutral
ph
monom
homotrim
maintain
hairpin
structur
ntermin
helix
residu
ctermin
helix
residu
join
extend
loop
residu
antiparallel
fashion
postfus
state
acid
ph
monom
still
retain
hairpin
structur
middl
portion
residu
origin
long
helix
unfold
form
revers
turn
ctermin
helix
residu
jackknif
back
lie
antiparallel
newli
form
ntermin
long
helix
residu
result
reloc
fp
dash
line
previous
buri
posit
expos
posit
figur
prepar
use
pymol
program
delano
http
wwwpymolorg
xray
crystal
structur
ha
neutral
ph
pdb
id
fleuri
et
al
low
ph
pdb
id
bullough
et
al
download
protein
data
bank
http
wwwrcsborgpdbhomehomedo
known
peptid
substrat
analog
inhibitor
decrvkrcmk
furin
could
block
hpai
iav
replic
et
al
later
observ
decrvkrcmk
inhibit
furin
also
ubiquit
type
ii
transmembran
serin
proteas
mspl
splice
variant
trypsintyp
proteas
plasmin
okumura
et
al
recent
kido
colleagu
report
mspl
may
also
serv
ha
process
proteas
hpai
iav
okumura
et
al
therefor
natur
inhibitor
mspl
human
may
also
use
lead
develop
habas
antiiav
drug
hamedi
membran
fusion
ha
activ
endosom
acid
ph
induct
irrevers
reorgan
ha
structur
wilson
et
al
bullough
et
al
sever
small
molecul
block
phdepend
conform
chang
ha
benzoquinon
hydroquinon
shown
inhibit
iav
infect
bodian
et
al
potent
hydroquinon
deriv
tertbutyl
hydroquinon
tbhq
fig
inhibit
iav
infect
low
micromolar
level
bodian
et
al
improv
molecular
dock
analysi
group
identifi
two
new
inhibitor
potent
iav
fusion
inhibitori
activ
ic
ic
fig
hoffman
et
al
tbhq
could
induc
drugresist
mutat
subunit
hoffman
et
al
suggest
act
protein
xray
crystallograph
studi
indic
tbhq
bind
lock
trimer
neutralph
conform
interact
tbhq
three
ioniz
amino
acid
site
one
monom
anoth
monom
fig
notabl
tbhq
inhibit
subtyp
avian
influenza
viru
inhibit
subtyp
viru
subtyp
intermonom
salt
bridg
subtyp
prefer
form
salt
bridg
result
subtyp
well
order
tbhq
site
access
russel
et
al
screen
chemic
librari
scientist
wyethayerst
research
identifi
three
compound
nsubstitut
piperidin
cl
analog
cl
fig
inhibitori
activ
subtyp
iav
ic
low
micromolar
level
plotch
et
al
analysi
ha
gene
mutant
virus
resist
compound
show
singl
amino
acid
mutat
cluster
stem
region
ha
trimer
near
fp
computerassist
molecular
model
reveal
could
dock
pocket
region
result
suggest
occup
pocket
may
interfer
low
phinduc
structur
rearrang
ha
disrupt
ionic
hydrophob
forc
maintain
ha
prefusogen
state
block
movement
polypeptid
chain
conform
reorgan
plotch
et
al
research
shionogi
discoveri
research
laboratori
japan
identifi
sever
hamedi
membran
fusion
inhibitor
stachyflin
deriv
fig
purifi
ferment
broth
stachybotri
sp
yoshimoto
et
al
stachyflin
effect
inhibit
infect
subtyp
iav
ic
low
level
shown
stachyflin
interf
low
phinduc
conform
chang
ha
therebi
block
hamedi
viruscel
fusion
analysi
ha
gene
sequenc
iav
variant
resist
stachyflin
reveal
two
amino
acid
substitut
subunit
ha
protein
enough
confer
stachyflinresist
phenotyp
ha
protein
yoshimoto
et
al
suggest
bind
site
stachyflin
locat
subunit
group
design
synthes
sever
stachyflin
deriv
acetylstachyflin
fig
improv
oral
avail
antivir
activ
yoshimoto
et
al
minagawa
et
al
inform
develop
class
antiiav
drug
avail
late
investig
bristol
myer
squibb
identifi
novel
iav
fusion
inhibitor
fig
inhibit
awsn
viru
replic
ic
effect
subtyp
virus
test
luo
et
al
studi
group
indic
inhibit
iav
infect
specif
interact
ha
protein
repress
conform
chang
ha
induc
lowph
sequenc
analys
ha
gene
variant
resist
map
amino
acid
substitut
respons
drug
resist
region
locat
near
n
terminu
suggest
compound
inhibit
hamedi
membran
fusion
target
ntermin
domain
subunit
luo
et
al
research
eli
lilli
found
podocarp
acid
deriv
fig
could
effect
inhibit
infect
iav
strain
affect
earli
step
viral
replic
staschk
et
al
genet
analysi
resist
reassort
virus
indic
ha
protein
confer
phenotyp
mutat
cluster
interfac
region
near
fp
phofinactiv
resist
mutant
increas
ph
unit
compar
wildtyp
virus
data
suggest
may
interact
neutral
ph
conform
ha
result
prevent
lowphinduc
chang
ha
fusogen
conform
earli
sever
peptid
deriv
domain
found
highli
potent
inhibit
membran
fusion
replic
jiang
et
al
wild
et
al
lu
et
al
one
gener
name
enfuvirtid
brand
name
new
class
antihiv
drug
known
hiv
fusionentri
inhibitor
treatment
hivinfect
patient
fail
respond
current
antiretrovir
therapeut
kilbi
eron
later
proven
inhibit
viral
fusion
bind
domain
interf
fusogen
sixhelix
bundl
core
format
chan
et
al
weissenhorn
et
al
liu
et
al
discoveri
antihiv
peptid
open
new
avenu
develop
viral
fusionentri
inhibitor
virus
class
membran
fusion
protein
respiratori
syncyti
viru
rsv
measl
viru
lambert
et
al
ebola
viru
weissenhorn
et
al
nipah
hendra
virus
xu
et
al
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
xu
et
al
zhu
et
al
sinc
iav
also
viru
class
membran
fusion
protein
sever
group
attempt
identifi
antiiav
peptid
use
similar
approach
success
report
far
possibl
limit
develop
antiiav
peptid
unlik
envelop
glycoprotein
chang
conform
induc
receptor
bind
mediat
membran
fusion
act
cell
surfac
neutral
ph
iav
ha
mediat
membran
fusion
endosom
acid
ph
peptid
deriv
region
even
interact
region
vitro
neutral
ph
may
effect
inhibit
hamedi
membran
fusion
peptid
enter
cell
endosom
becom
inact
acid
ph
chemic
strategi
term
hydrocarbon
stapl
walenski
et
al
design
cellpenetr
helic
peptid
activ
zhang
et
al
may
adapt
develop
antiiav
peptid
target
subunit
ha
anoth
strategi
identifi
small
molecul
weight
compound
cellpenetr
abil
oral
avail
interact
domain
ha
block
format
trimer
heterodim
iav
fusionentri
inhibitor
howev
identif
proper
pocket
prefus
intermedi
conform
prerequisit
screen
small
molecul
antiiav
compound
target
sequenc
pocket
region
domain
highli
conserv
hydrophob
pocket
play
critic
role
viral
fusion
chan
et
al
ji
et
al
therefor
peptid
hiv
fusion
inhibitor
contain
pocket
bind
sequenc
dwyer
et
al
small
molecul
hiv
fusion
inhibitor
target
conserv
pocket
region
eg
wang
et
al
reluct
induc
drugresist
mutat
viru
may
surviv
mutat
highli
conserv
pocket
region
therefor
effort
exert
identif
peptid
nonpeptid
iav
fusionentri
inhibitor
target
sequenceconserv
portion
ha
especi
interfac
coiledcoil
contact
carr
kim
vaccin
effect
way
prevent
elimin
futur
influenza
pandem
howev
current
licens
season
influenza
vaccin
ineffect
newli
emerg
influenza
virus
therefor
develop
vaccin
iav
especi
might
induc
highli
pathogen
ie
hpai
remain
prioriti
convent
approach
develop
influenza
vaccin
mainli
base
inactiv
liveattenu
influenza
virus
treanor
et
al
sasaki
et
al
vaccin
shown
promis
effici
immunogen
costsav
clinic
trial
ruben
mitchel
et
al
obviou
disadvantag
includ
relianc
avail
embryon
chicken
egg
may
short
suppli
birdflu
outbreak
ii
length
vaccin
gener
time
vaccin
strain
select
avail
formul
vaccin
iii
potenti
side
effect
peopl
allergi
egg
protein
iv
safeti
concern
potenti
introduct
live
viru
human
popul
ellebedi
webbi
limit
convent
vaccin
highlight
need
explor
new
approach
design
develop
influenza
vaccin
ha
one
import
iav
surfac
protein
major
target
induc
neutral
antibodi
respons
thu
main
constitu
influenza
vaccin
formul
differ
categori
habas
influenza
vaccin
develop
evalu
clinic
trial
varieti
influenza
vaccin
develop
base
dna
encod
iav
comparison
efficaci
dna
vaccin
code
ha
protein
dnaha
code
iav
protein
demonstr
dnaha
effect
induc
high
level
antibodi
cell
respons
dna
vaccin
encod
na
nucleoprotein
np
matrix
protein
protein
thu
afford
better
protect
other
prevent
immun
mice
challeng
homolog
heterolog
virus
patel
et
al
addit
vaccin
mice
dnaha
could
significantli
increas
surviv
rate
chen
et
al
clinic
trial
show
trival
dna
vaccin
consist
three
plasmid
express
ha
differ
season
influenza
viru
strain
safe
could
elicit
immunolog
respons
protect
human
subject
viru
challeng
jone
et
al
monoval
dna
vaccin
contain
haencod
plasmid
also
shown
safe
effect
phase
clinic
trial
smith
et
al
howev
dnabas
vaccin
also
disadvantag
includ
risk
affect
gene
control
cell
growth
ii
potenti
induc
antidna
antibodi
respons
iii
possibl
toxic
effect
inject
site
repeat
dose
use
du
et
al
viral
vector
select
altern
approach
develop
habas
vaccin
report
viral
vector
express
influenza
virus
includ
newcastl
diseas
viru
ndv
dinapoli
et
al
parainfluenza
viru
type
tompkin
et
al
vesicular
stomat
viru
vsv
barefoot
et
al
adenoviru
gao
et
al
modifi
vaccinia
viru
ankara
mva
kreijtz
et
al
b
shown
efficaci
preclin
trial
dinapoli
et
al
report
ndvvector
vaccin
express
ha
hpai
develop
high
level
neutral
antibodi
homolog
heterolog
strain
hpai
iav
protect
african
green
monkey
homolog
viru
challeng
dinapoli
et
al
accord
kreijtz
et
al
recombin
mva
vector
express
ha
avietnam
could
induc
crossreact
antibodi
respons
protect
vaccin
cynomolgu
macaqu
viral
infect
respiratori
tract
prevent
develop
sever
necrot
bronchointerstiti
pneumonia
kreijtz
et
al
howev
note
immunogen
viralvectorbas
vaccin
could
suppress
presenc
preexist
immun
vector
potenti
caus
harm
immun
respons
vaccin
subject
barouch
et
al
lasaro
ertl
envelop
viruslik
particl
vlp
vaccin
contain
ha
na
influenza
viru
may
produc
insect
mammalian
cell
via
simultan
express
two
protein
togeth
viral
core
protein
retrovir
gag
protein
hayn
new
influenza
vaccin
approach
provid
overal
advantag
convent
method
improv
immunogen
protect
previou
result
demonstr
vlp
contain
ha
na
protein
induc
high
titer
antibodi
andor
longterm
protect
heterolog
well
homolog
iav
bright
et
al
kang
et
al
bival
influenza
vlp
vaccin
contain
ha
viru
viru
induc
neutral
activ
complet
inhibit
infect
homolog
strain
heterolog
strain
includ
strain
well
strain
ahong
viru
quan
et
al
impli
influenza
vlp
particularli
multival
vlp
use
altern
method
develop
safe
effect
vaccin
control
spread
influenza
virus
recombin
subunit
vaccin
consid
attract
develop
vaccin
iav
amorij
et
al
biesova
et
al
sinc
kind
vaccin
gener
contain
infecti
materi
thu
noninfecti
safe
use
du
et
al
addit
current
avail
advanc
recombin
technolog
would
benefit
expediti
vaccin
product
furthermor
high
puriti
recombin
protein
vaccin
would
enabl
administr
much
higher
dose
without
signific
increas
side
effect
human
subject
especi
immunodefici
highrisk
medic
condit
safdar
cox
current
habas
subunit
vaccin
test
variou
anim
model
evalu
human
clinic
trial
wei
et
al
king
et
al
report
shown
ecoliexpress
recombin
vaccin
contain
ha
formul
alum
induc
high
immun
respons
particularli
haspecif
antibodi
young
outbr
mice
antibodi
level
consist
fda
guidelin
vaccin
epidem
pandem
influenza
biesova
et
al
phase
clinic
trial
subunit
influenza
ahong
vaccin
healthi
adult
shown
subunit
vaccin
safe
abl
induc
antibodi
respons
level
similar
induc
whole
viru
particl
stephenson
et
al
although
safe
easi
produc
habas
subunit
vaccin
might
induc
strong
immun
respons
particularli
young
children
phenomenon
evidenc
trival
recombin
baculovirusexpress
ha
influenza
vaccin
shown
induc
less
immunogen
egggrown
trival
influenza
vaccin
healthi
children
age
month
king
et
al
therefor
crucial
improv
immunogen
habas
subunit
vaccin
conform
ha
protein
play
import
role
recent
studi
indic
possibl
induc
stronger
neutral
antibodi
respons
ha
highmolecularweight
oligomer
form
trimer
monomer
form
wei
et
al
continu
threat
influenza
pandem
urgent
need
develop
vaccin
provid
protect
current
identifi
viru
strain
also
futur
emerg
viru
strain
rapid
mutat
protect
ha
antigen
circul
iav
requir
reformul
influenza
vaccin
broad
specif
influenza
vaccin
direct
conserv
region
ha
protein
would
great
chanc
meet
requir
fp
region
subunit
contain
conserv
sequenc
maintain
high
homolog
across
iav
du
et
al
recent
studi
indic
monoclon
antibodi
mab
recogn
highli
conserv
helic
region
membraneproxim
stem
could
neutral
viru
block
conform
rearrang
associ
viral
membran
fusion
ekiert
et
al
studi
reveal
mab
bind
glfgaiagf
conserv
fp
region
complet
protect
mice
lethal
challeng
two
differ
clade
hpai
iav
prabhu
et
al
sui
et
al
identifi
broad
neutral
activ
mab
bind
site
locat
highli
conserv
fpinvolv
pocket
stem
region
ha
sui
et
al
addit
conserv
fp
region
conserv
region
ha
protein
iav
may
also
serv
import
vaccin
target
human
mab
recent
obtain
use
peripher
blood
lymphocyt
two
influenzavaccin
volunt
show
strong
global
neutral
strain
recogn
sequenc
similar
amino
acid
residu
protein
two
sequenc
fairli
conserv
clearli
separ
cluster
differ
host
origin
kubotakoketsu
et
al
yamashita
et
al
anoth
mab
map
least
two
conserv
site
ha
residu
also
protect
mice
lethal
challeng
four
strain
repres
current
major
genet
popul
clade
chen
et
al
use
largescal
sequenc
analysi
ha
protein
correspond
subtyp
sahini
et
al
identifi
nine
conserv
region
five
structur
characterist
suitabl
antivir
antipeptid
respons
sahini
et
al
ha
major
surfac
protein
iav
mediat
viral
bind
membran
fusion
viral
entri
receptor
bind
specif
determin
speci
specif
iav
infect
eg
human
avian
iav
prefer
bind
sialic
acid
respect
studi
need
understand
potenti
role
ha
acquisit
human
transmiss
animalorigin
iav
soiv
strain
determin
crystal
structur
complex
complex
complex
trimer
provid
import
inform
understand
phinduc
conform
chang
ha
prefus
intermedi
postfus
state
identif
target
hatrim
prefus
intermedi
conform
develop
antiiav
drug
given
fact
sequenc
conform
subtyp
iav
much
differ
hpai
subtyp
worthwhil
explor
key
residu
contribut
differ
conform
key
residu
may
hot
spot
antiiav
drug
design
screen
especi
drug
high
mortal
iav
although
seri
antiiav
drug
target
na
protein
current
avail
emerg
drugresist
virus
due
widespread
use
drug
rais
great
concern
ineffect
newli
emerg
iav
soiv
strain
hpai
virus
le
et
al
mitrasinov
thu
essenti
develop
novel
antiiav
drug
new
target
number
proteinbas
small
molecul
antiiav
agent
shown
interfer
hamedi
membran
fusion
block
cleavag
function
subunit
mediat
host
proteas
inhibit
low
phmediat
conform
chang
ha
howev
drug
low
potenc
inhibit
iav
replic
still
long
way
develop
inhibitor
clinic
usabl
antiiav
therapeut
success
strategi
discov
develop
peptid
antihiv
drug
enfuvirtid
appli
identif
peptid
fusion
inhibitor
virus
bear
class
transmembran
protein
includ
iav
howev
antiiav
peptid
ever
report
suggest
difficulti
identifi
peptid
enter
cell
endosom
block
fusion
viral
endosom
membran
mediat
ha
acid
ph
environ
hope
design
screen
cellpermiss
short
peptid
small
molecular
weight
organ
compound
interact
target
block
format
ha
fusionact
core
though
peptid
drug
expens
worthwhil
develop
save
live
patient
influenza
pandem
antigen
shift
drift
great
challeng
develop
effect
safe
vaccin
diverg
iav
especi
newli
emerg
hpai
subtyp
may
caus
futur
influenza
pandem
sinc
ha
contain
major
neutral
epitop
serv
import
target
develop
antiiav
vaccin
number
habas
dna
vaccin
viral
vector
vaccin
viruslik
particl
vaccin
recombin
subunit
vaccin
develop
preclin
clinic
studi
identif
neutral
epitop
conserv
fp
region
ha
protein
demonstr
potenti
conserv
region
serv
import
vaccin
target
accordingli
bring
hope
develop
influenza
vaccin
may
induc
crossprotect
diverg
iav
ekiert
et
al
prabhu
et
al
sui
et
al
du
et
al
effect
epitop
expect
found
conserv
region
ha
vaccin
target
futur
prevent
influenza
pandem
dnaha
dna
vaccin
code
ha
protein
fp
fusion
peptid
ha
hemagglutinin
hpai
highli
pathogen
avian
influenza
iav
influenza
viru
ird
infant
respiratori
distress
syndrom
mab
monoclon
antibodi
mva
modifi
vaccinia
viru
ankara
matrix
protein
na
neuraminidas
ndv
newcastl
diseas
viru
np
nucleoprotein
parainfluenza
viru
type
rsv
respiratori
syncyti
viru
sarscov
sever
acut
respiratori
syndromeassoci
coronaviru
soiv
swineorigin
influenza
viru
vlp
envelop
viruslik
particl
vsv
vesicular
stomat
viru
